<DOC>
	<DOCNO>NCT02151864</DOCNO>
	<brief_summary>The purpose study test safety determine maximum safe dose experimental drug call LDE225 ( hedgehog inhibitor ) people liver cancer . We identify hedgehog dysregulation novel mechanism hepatocarcinogenesis hepatic fibrosis/cirrhosis . Therefore , hypothesize hedgehog inhibitor may ideal drug target treat hepatocellular carcinoma ( HCC ) Child-Pugh A cirrhosis ( CPA ) .</brief_summary>
	<brief_title>LDE225 Patients With Advanced Metastatic Hepatocellular Carcinoma Child-Pugh A/B7 Cirrhosis</brief_title>
	<detailed_description>This open-label , single institution , Phase I , 3+3 dose escalation study LDE225 patient advance metastatic hepatocellular carcinoma Child-Pugh A Cirrhosis intolerant sorafenib . The investigational treatment cycle ( 21 day ) consist daily oral LDE225 . Dose escalation perform serial patient cohort . Up six patient study dose level . Safety clinical data tabulate decision open next cohort level responsibility principal investigator . Dose escalation base dose-limiting toxicity encounter Day 42 investigational treatment . Patients dose flat scale daily dose LDE225 prescribe dose cohort .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Age 18 year old Pathological confirmation advance metastatic HCC HCC amenable surgical resection , liver transplantation , chemoembolization , ablation therapy Patients ChildPugh A ChildPugh B7 ( due low albumin elevate INR bilirubin ) cirrhosis allow . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 At least one measurable site disease ( define Response Evaluation Criteria Solid Tumors ) Patients adequate bone marrow , liver renal function Inability tolerate firstline treatment sorafenib Patient amenable liver tumor biopsy ChildPugh B ChildPugh C cirrhosis Patients know Gilbert 's Syndrome Ongoing alcohol use abuse define &gt; average 2 alcoholic beverage daily Patients major surgery within 4 week initiation study medication Patients know brain metastasis Patients concurrent uncontrolled medical condition may interfere participation study Patients know human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness Patients Hepatitis B and/or Hepatitis C infection exclude follow viral suppressive agent : boceprevir ( Victrelis ) , ribavirin ( Rebetol , Ribatab , Ribasphere ) , telaprevir ( Incivek ) Patients unable take oral drug lack physical integrity upper gastrointestinal tract know malabsorption syndromes Patients previously treat systemic LDE225 Hh pathway inhibitor Patients neuromuscular disorder concomitant treatment drug recognize cause rhabdomyolysis Patients plan embark new strenuous exercise regimen initiation study treatment Patients take part experimental drug study within 4 week initiate study treatment LDE225 Patients receive antineoplastic therapy concurrently within 2 week start study treatment LDE225 Patients receive anticoagulation antiplatelet therapy Patients receive treatment medication know strong inhibitor inducer cytochrome P450 3A4 ( CYP3A4/5 ) drug metabolize cytochrome P450 2B6 ( CYP2B6 ) cytochrome P450 2C9 ( CYP2C9 ) narrow therapeutic index , discontinue start study treatment LDE225 Impaired cardiac function clinically significant heart disease Patients contraindication MRI and/or MRI contrast agent Pregnant nursing ( lactate ) woman Women childbearing potential must use highly effective contraception study 6 month final dose study treatment Sexually active male unwilling use condom intercourse take drug 6 month stop investigational medication agree father child period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>Child-Pugh A</keyword>
	<keyword>Hedgehog</keyword>
</DOC>